ETR:MDG1 - Medigene Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: €0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
€2.74
▼ -0.09 (-3.18%)

This chart shows the closing price for MDG1 by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medigene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDG1 and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDG1

Analyst Price Target is €0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Medigene in the last 3 months. The average price target is €0.00, with a high forecast of €0.00 and a low forecast of €10,000,000.00. The average price target represents a -100.00% upside from the last price of €2.74.

This chart shows the closing price for MDG1 for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Medigene. This rating has held steady since October 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2019Baader BankSet Price TargetNeutral€11.00
4/12/2019Baader BankSet Price TargetNeutral€11.00
3/8/2019Independent ResearchSet Price TargetNeutral€10.00
1/7/2019Baader BankSet Price TargetBuy€17.00
1/1/2019Baader BankSet Price TargetBuy€17.00
12/26/2018Baader BankSet Price TargetBuy€17.00
12/20/2018Baader BankSet Price TargetBuy€17.00
12/3/2018Baader BankSet Price TargetBuy€17.00
11/28/2018Independent ResearchSet Price TargetNeutral€10.80
11/21/2018Baader BankSet Price TargetBuy€17.00
11/9/2018Baader BankSet Price TargetBuy€22.00
8/30/2018Baader BankSet Price TargetBuy€22.00
8/21/2018Baader BankSet Price TargetBuy€22.00
8/10/2018Independent ResearchSet Price TargetNeutral€15.50
8/7/2018Baader BankSet Price TargetBuy€22.00
6/22/2018Oddo BhfSet Price TargetNeutral€14.00
5/25/2018Independent ResearchSet Price TargetNeutral€16.50
5/14/2018Independent ResearchSet Price TargetNeutral€16.50
4/16/2018Baader BankSet Price TargetBuy€22.00
4/4/2018Baader BankSet Price TargetBuy€22.00
3/29/2018Baader BankSet Price TargetBuy€22.00
3/23/2018Oddo BhfSet Price TargetNeutral€13.00
3/22/2018Independent ResearchSet Price TargetNeutral€16.50
3/22/2018Baader BankSet Price TargetBuy€19.00
12/11/2017Baader BankSet Price TargetBuy€19.00
12/6/2017Independent ResearchSet Price TargetNeutral€12.50
11/14/2017Independent ResearchSet Price TargetNeutral€12.00
11/9/2017Baader BankSet Price TargetBuy€19.00
9/4/2017Independent ResearchSet Price TargetNeutral€13.00
8/8/2017Oddo SecuritiesSet Price TargetBuy€12.00
8/3/2017Baader BankSet Price TargetBuy€19.00
5/29/2017Oddo SecuritiesSet Price TargetBuy€13.00
5/29/2017Independent ResearchSet Price TargetNeutral€12.00
5/20/2017Baader BankSet Price TargetBuy€19.00
5/20/2017Oddo SecuritiesSet Price TargetBuy€13.00
5/20/2017Independent ResearchSet Price TargetNeutral€12.00
(Data available from 1/22/2017 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Medigene logo
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
Read More

Today's Range

Now: €2.74
Low: €2.72
High: €2.84

50 Day Range

MA: €3.03
Low: €2.70
High: €3.55

52 Week Range

Now: €2.74
Low: €2.65
High: €4.97

Volume

19,713 shs

Average Volume

306,207 shs

Market Capitalization

$67.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Medigene?

The following Wall Street sell-side analysts have issued research reports on Medigene in the last twelve months:
View the latest analyst ratings for MDG1.

What is the current price target for Medigene?

0 Wall Street analysts have set twelve-month price targets for Medigene in the last year. has the lowest price target set, forecasting a price of €10,000,000.00 for Medigene in the next year.
View the latest price targets for MDG1.

What is the current consensus analyst rating for Medigene?

Medigene currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MDG1.

How do I contact Medigene's investor relations team?

Medigene's physical mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The company's listed phone number is +49-89-2000330. The official website for Medigene is www.medigene.de.